Avanir Pharma (AVNR) files a $150M mixed shelf. The drug developer only says it will use any...

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

Avanir Pharma (AVNR) files a $150M mixed shelf. The drug developer only says it will use any proceeds for general corporate purposes, which could include financing clinical trials and/or commercializing Nuedexta. Avanir had $65.8M in cash on its balance sheet as of March 30, and $29.1M in debt.